The Gamaleya Center is conducting preclinical trials of a vaccine that will provide protection against several strains of coronavirus. This was reported by Interfax with reference to the head of the center, Alexander Gintsburg.
According to him, the new technology is capable of forming protective immunity not to one, but to four or five variants of the virus.
“Thus, we will not have to make 3-4-5 different” Satellites V “, it will be a kind of cluster warhead,” Gunzburg added.
The Gamaleya Center is the developer of the first Russian vaccine against coronavirus, Sputnik V, which was registered in August last year. The drug is now approved in 59 countries with a total population of over 1.5 billion people. In terms of the number of approvals received by state regulators, the Russian vaccine ranks second in the world.
In early February, the scientific journal Lancet published the results of the third phase of clinical trials of Sputnik V, confirming its high efficacy and safety: the drug fully protects against the severe course of COVID-19.